High-dose IL-2 was approved by the FDA for the treatment of patients with metastatic melanoma and metastatic renal carcinoma (3) but caused severe systemic toxicity, including capillary leak syndrome, hypotension, hypoxia, and oliguric renal failure. Here, IL2 is linked to capillary leak syndrome.